4.5 Article

Multiple effects of digoxin on subsets of cancer-associated genes through the alternative splicing pathway

Journal

BIOCHIMIE
Volume 106, Issue -, Pages 131-139

Publisher

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biochi.2014.08.013

Keywords

Digoxin; Cardiac glycosides; Alternative splicing; SRSF3; Drug repositioning

Funding

  1. National Defense Medical Bureau [MAB-102-39, MAB-102-35]
  2. Tri-Service General Hospital, Taiwan, ROC [TSGH-C101-031]

Ask authors/readers for more resources

The signaling characteristics of Na+/K+-ATPase are distinct from its ion pumping activity. Cardiac glycosides modulate the Na+/K+-ATPase protein complex upon binding, activate downstream signaling pathways and increase [Ca2+](i). Recent studies demonstrate that the depletion of p53 and hypoxia-induced factor 1 alpha proteins is caused by cardiac glycosides. However, the detailed mechanisms governing this process are not well known. In this study, we showed that the depletion of p53 proteins by digoxin involved not only inhibition of protein synthesis but also inhibition at the post-transcriptional level. Post-transcriptional regulation occurs via down-regulation of SRSF3, the primary splicing factor responsible for the switch from p53 alpha to the p53 beta isoform. Digoxin also modulated G2/M arrest, DNA damage and apoptosis through the p53-dependent pathway in HeLa cells. In addition, digoxin was involved in epithelial-mesenchymal-transition progression via E-cadherin reduction and snail induction. Digoxin had similar effects to caffeine, another SRSF3-reduced agent, on the cell cycle profile and DNA damage of cells. Interestingly, combined digoxin and caffeine treatment blocked cell cycle progression and conferred resistance to cell death via snail induction. These findings demonstrate that down-regulation of splicing factor, such as SRSF3, to alter cell cycle progression, cell death and invasion is a potential target for the drug repositioning of cardiac glycosides. (C) 2014 Elsevier B.V. and Societe francaise de biochimie et biologie Moleculaire (SFBBM). All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available